Antibody-Dual-Drug Conjugation (AD2C): Spotlighting an Engineering-Free Platform to Overcome Payload Resistance & Tumor Heterogeneity With Plug & Play Upgrade of Existing ADCs
11:30 am - Wednesday 14th October 2026
- Introducing the AD2C platform: Dual payload conjugation without antibody engineering, unnatural amino acids, or enzymatic ligation
- Overcoming payload resistance, the fastest-growing unmet ADC need, by delivering orthogonal mechanisms in one molecule
- Advancing ACE723, an anti-GPC3 dual payload ADC through IND-enabling studies to US and China IND-enabling submissions
